Literature DB >> 15585635

Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses.

Liang Zhao1, M Guillaume Wientjes, Jessie L-S Au.   

Abstract

Isobologram and combination index (CI) analyses are the two most popular methods for evaluating drug interactions in combination cancer chemotherapy. As the commonly used CI-based software program uses linear regression, our first objective was to evaluate the effects of logarithmic data transformation on data analysis and conclusions. Monte-Carlo simulations were conducted with experimentally relevant parameter values to generate error-containing effect or concentration-effect data of single agents and combinations. The simulated data were then analyzed with linear and nonlinear regression. The results showed that data transformation reduced the accuracy and precision of the regression-derived IC(50), curve shape parameter and CI values. Furthermore, as neither isobologram nor CI analyses provide output of concentration-effect curves for investigator evaluation, our second objective was to develop a method and the associated computer program/algorithm to (a) normalize drug concentrations in IC(50) equivalents and thereby enable simultaneous presentation of the curves for single agents and combinations in a single plot for visual inspection of potential curve shifts, (b) analyze concentration-effect data with nonlinear regression, and (c) use the curve shift analysis simultaneously with isobologram and CI analyses. The applicability of this method was shown with experimentally obtained data for single agent doxorubicin and suramin and their combinations in cultured tumor cells. In summary, this method, by incorporating nonlinear regression and curve shift analysis, although retaining the attractive features of isobologram and CI analyses, reduced the potential errors introduced by logarithmic data transformation, enabled visual inspection of data variability and goodness of fit of regression analysis, and simultaneously provided information on the extent of drug interaction at different combination ratios/concentrations and at different effect levels.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15585635     DOI: 10.1158/1078-0432.CCR-04-1087

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  135 in total

1.  HGF rescues colorectal cancer cells from EGFR inhibition via MET activation.

Authors:  David Liska; Chin-Tung Chen; Thomas Bachleitner-Hofmann; James G Christensen; Martin R Weiser
Journal:  Clin Cancer Res       Date:  2010-11-22       Impact factor: 12.531

2.  The histone deacetylase inhibitor panobinostat demonstrates marked synergy with conventional chemotherapeutic agents in human ovarian cancer cell lines.

Authors:  Daniel R Budman; Julia Tai; Anthony Calabro; Veena John
Journal:  Invest New Drugs       Date:  2010-06-09       Impact factor: 3.850

3.  Polymer-caged nanobins for synergistic cisplatin-doxorubicin combination chemotherapy.

Authors:  Sang-Min Lee; Thomas V O'Halloran; SonBinh T Nguyen
Journal:  J Am Chem Soc       Date:  2010-11-15       Impact factor: 15.419

4.  ANOVA and the analysis of drug combination experiments.

Authors:  John C Ashton
Journal:  Nat Methods       Date:  2015-12       Impact factor: 28.547

5.  XPO1/CRM1 Inhibition Causes Antitumor Effects by Mitochondrial Accumulation of eIF5A.

Authors:  Takahito Miyake; Sunila Pradeep; Sherry Y Wu; Rajesha Rupaimoole; Behrouz Zand; Yunfei Wen; Kshipra M Gharpure; Archana S Nagaraja; Wei Hu; Min Soon Cho; Heather J Dalton; Rebecca A Previs; Morgan L Taylor; Takeshi Hisamatsu; Yu Kang; Tao Liu; Sharon Shacham; Dilara McCauley; David H Hawke; John E Wiktorowicz; Robert L Coleman; Anil K Sood
Journal:  Clin Cancer Res       Date:  2015-04-15       Impact factor: 12.531

6.  Alterations of microRNA expression patterns in human cervical carcinoma cells (Ca Ski) toward 1'S-1'-acetoxychavicol acetate and cisplatin.

Authors:  Neoh Hun Phuah; Lionel L A In; Mohamad Nurul Azmi; Halijah Ibrahim; Khalijah Awang; Noor Hasima Nagoor
Journal:  Reprod Sci       Date:  2012-09-25       Impact factor: 3.060

7.  Mechanistic Study of Inhibitory Effects of Atorvastatin and Docetaxel in Combination on Prostate Cancer.

Authors:  Xuan Chen; Yue Liu; Jian Wu; Huarong Huang; Zhiyun Du; Kun Zhang; Daiying Zhou; Kaylyn Hung; Susan Goodin; Xi Zheng
Journal:  Cancer Genomics Proteomics       Date:  2016 Mar-Apr       Impact factor: 4.069

8.  miR-195 potentiates the efficacy of microtubule-targeting agents in non-small cell lung cancer.

Authors:  Xiaojie Yu; Yiqiang Zhang; Xiuye Ma; Alexander Pertsemlidis
Journal:  Cancer Lett       Date:  2018-04-13       Impact factor: 8.679

9.  HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL.

Authors:  Matko Kalac; Luigi Scotto; Enrica Marchi; Jennifer Amengual; Venkatraman E Seshan; Govind Bhagat; Netha Ulahannan; Violetta V Leshchenko; Alexis M Temkin; Samir Parekh; Benjamin Tycko; Owen A O'Connor
Journal:  Blood       Date:  2011-07-19       Impact factor: 22.113

10.  Identification of unique synergistic drug combinations associated with downexpression of survivin in a preclinical breast cancer model system.

Authors:  Daniel R Budman; Anthony Calabro; Lisa Rosen; Martin Lesser
Journal:  Anticancer Drugs       Date:  2012-03       Impact factor: 2.248

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.